Objective: To determine whether biomarkers of health such as serum levels of free triiodothyronine (fT3), total triiodothyronine (TT3), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity C-reactive protein (hsCRP) impact the cognitive functioning of coronary artery disease (CAD) patients. Method: About 278 patients were evaluated for socio-demographic and clinical risk factors as well as fT3, TT3, NT-proBNP, and hsCRP serum levels. Cognitive functioning measures included the Mini-Mental State Examination, Digit Span Test, Digit Symbol Substitution Test (DSST), and Trail Making Test A (TMTA). Depressive symptoms were assessed with the Hospital Anxiety and Depression Scale. Results: Lower fT3 concentrations were associated with longer completion time of the DSST and TMTA. Elevated levels of NT-proBNP were also associated with inferior performance on TMTA independently of socio-demographic characteristics, clinical risk factors, and depression symptoms. Conclusions: Lower fT3 concentrations and higher levels of NT-proBNP were associated with worse cognitive functioning in CAD patients.
Introduction
Reduced serum triiodothyronine concentration (T3), and increased concentration of both N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hsCRP) are common in patients with coronary artery disease (CAD). Moreover, these biomarkers have been associated with worse health status and unfavorable CAD prognosis (Brozaitiene, Mickuviene, Podlipskyte, Burkauskas, & Bunevicius, 2016; Koenig, 2013) .
Previous studies linked elevated pro-inflammatory cytokine and NT-proBNP concentrations with worse cognitive functioning in the general population (Mirza et al., 2016) , and in patients with stroke (Bunevicius et al., 2015) and diabetes (Feinkohl et al., 2013) . However, the association of pro-inflammatory cytokine and NT-proBNP concentrations with cognitive functioning in CAD patients after acute coronary syndromes (ACS) remains to be established.
To the best of our knowledge, there are no studies exploring the association of the hypothalamic-pituitary-thyroid axis hormone concentrations with cognitive functioning in patients with established CAD. In addition to the lack of such an association in CAD patients, recent studies provide mixed findings regarding the association in other patient groups. For example, it was suggested that subclinical hyperthyroidism is associated with elevated risk for dementia in the general population (Vadiveloo, Donnan, Cochrane, & Leese, 2011) . However, others have not found a link between subclinical hyperthyroidism and cognitive decline in elderly patients with vascular disease risk factors (Wijsman et al., 2013) . Another study of post-menopausal women aged from 50 to 65 years showed that lower free T3 (fT3) concentrations were associated with worse results on tests of psychomotor speed (Bojar, Bejga, Witczak, Łyszcz, & Makara-Studzinska, 2014 ). Further studies exploring a possible link between thyroid hormone concentrations and cognitive functioning are warranted.
While early cognitive impairment remains an important predictor of negative outcomes of CAD patients (Fried et al., 1998) , finding factors related to cognitive functioning would help to better understand current CAD treatment patterns and outcomes, with significant potential for improving patient care. For mental health specialists working in a rehabilitation setting, it would also be important to ascertain how cognitive functioning tests performed during rehabilitation could be interpreted in light of a possible association between thyroid hormones, NT-proBNP, hsCRP, and cognitive functioning. A better grasp of this association could lead to more accurate assessment of patient's health status.
In CAD patients undergoing rehabilitation after ACS, we aimed to investigate an association of fT3, total T3 (TT3), NT-proBNP, and hsCRP with cognitive functioning, while controlling for socio-demographic characteristics, clinical risk factors, and symptoms of depression.
Materials and Methods

Participants
The Regional Biomedical Research Ethics Committee approved the study procedures. Following the guiding principles of the Helsinki Declaration, all participants gave written informed consent prior to inclusion in the study. This study was conducted at the Cardiovascular Rehabilitation hospital of the Behavioral Medicine Institute of the Lithuanian University of Health Sciences in Palanga, Lithuania.
The study was conducted in a period from 2011 until 2013. In summary, 434 consecutive adult patients attending inpatient rehabilitation program admitted from 7 to 10 days after treatment for ACS (myocardial infarction [MI] or unstable angina pectoris) were approached. However, 156 (36%) patients were excluded from the study based on the following exclusion criteria: (a) age greater than 80 years (n = 26; 6%) due to significantly increased risk for dementia and Alzheimer's disease; (b) history of stroke and/or coronary artery bypass grafting (CABG; n = 78; 18%) because prior stroke and CABG put patients at elevated risk for cognitive decline; (c) other somatic diseases, such as kidney failure (n = 12; 3%) which can alter fT3, NT-pro-BNP, and hsCRP serum concentrations; (d) motor function impairment or communicative disabilities (n = 5; 1%) restricting of full engagement in cognitive testing; and (e) unwillingness to participate in the study (n = 35; 8%). The final study sample comprised 278 patients.
Study Design Overview
All study assessments were performed within 3 days of admission. During the Day 1 initial interview, a cardiologist evaluated subjects for socio-demographic characteristics and clinical risk factors including age, gender, education, current cardiac diagnosis, functional class as described in the guidelines provided by the New York Heart Association (NYHA; The Criteria Committee of the New York Heart Association, 1994), arterial hypertension, medication use, body mass index (BMI), history of diabetes mellitus, and smoking. Left ventricular ejection fraction (LVEF) was evaluated quantitatively by the study cardiologist through cardiac echocardiography. All participants had a blood sample collection on the second day following admission to the rehabilitation clinic. Within 3 days of agreeing to participate in the study, patients also filled out a questionnaire assessing subjectively experienced depression symptoms. The questionnaire was completed in a separate room without the presence of any medical professional. On the same day that they filled out the questionnaire, patients completed tests measuring cognitive functioning.
Evaluation of fT3, TT3, NT-pro-BNP, and hsCRP Concentrations
Venous blood samples were drawn after an overnight fast (minimum of 12-hr) for evaluation of fT3, TT3, NT-proBNP, and hsCRP serum concentrations. Blood was centrifuged and serum was stored frozen at -40°C. Serum concentrations of fT3 and TT3 were analyzed using automated enzyme immunoassay analyzer AIA 600/21/1800 (Tosoh Corporation). Serum concentration of NT-proBNP was assessed using the radio-immunoassay method (Roche Cobasanalyzer, Roche Diagnostics, UK). The chemiluminescent immunoassay method (Beckman Coulter Unicel DXC 600) was used to measure serum hsCRP concentrations.
Cognitive Functions
The Mini-Mental State Examination (MMSE) was used to assess global cognitive functioning (Folstein, Folstein, & McHugh, 1975) . Auditory attention, mental flexibility, psychomotor performance, and perceptual speed were tested using a standard battery of cognitive tests that included the Digit Span Test (DST) and Digit Symbol Substitution Test (DSST) from the Wechsler Adult Intelligence Scale (Wechsler, 1981) , and Trail Making Test A (TMTA; Strauss, Sherman, & Spreen, 2006) . These cognitive functioning assessment tests are recommended for identifying individuals in the early stages of cognitive impairment and have also been suggested for use as predictors of future cognitive impairment (Fabrigoule et al., 1998; Hachinski et al., 2006; Linn et al., 1995; Tombaugh, 2004) . These tests were also previously validated and used for research purposes in Lithuania (Bunevicius, Kazanavicius, Zalinkevicius, & Prange, 1999) .
Depression Symptoms
A study by Bunevicius and colleague (2006) has shown that patients with CAD with depressive symptoms had a higher prevalence of cardiac failure, higher NT-proBNP concentrations, and lower fT3 concentrations than patients with CAD but without depressive symptoms. Thus, in the present study, we included a measure of depressive symptom severity as a possible confounder in the association of cognitive functioning with thyroid hormones, NT-pro-BNP, and hsCRP concentrations.
From the Hospital Anxiety and Depression Scale (HADS) a 7-item depression subscale (HADS-D) was used to assess depressive symptom severity (Zigmond & Snaith, 1983) . A higher score on the HADS-D represents more severe symptoms of depression. A score greater or equal to 8 on the HADS-D indicate possible clinical depression. The HADS-D has good psychometric characteristics for identification of depressive disorders in Lithuanian CAD patients (Bunevicius et al., 2013) . Consistency of the HADS-D aligned with a Cronbach alpha coefficient of 0.751 in this study.
Statistical Analysis
Statistical analyses were conducted using version 17.0 of the SPSS for Windows statistical package (SPSS Inc, Chicago, IL). Normality of distribution of qualitative variables was tested using skewness statistic, kurtosis statistic, and one-sample Kolmogorov-Smirnov tests. NT-proBNP and hsCRP values were not normally distributed. Natural logarithm transformation was used for the NT-proBNP and hsCRP values in order to satisfy normality assumption required by the statistics used.
Univariate regression analysis was used to examine unadjusted associations of fT3, TT3, (ln)NT-proBNP, and (ln)hsCRP serum concentrations with scores on cognitive function tests. Bonferroni correction method for adjusting for multiple comparisons was used for p values in seven independent models for each cognitive functioning domain (.05/7 = .00714). All variables that were statistically significantly (p < .007) associated with cognitive functioning domain in univariate analyses were subsequently included in respective multivariate regression models. Thus, multivariate linear regression analyses were performed to determine if fT3, TT3, (ln)NT-proBNP, and (ln)hsCRP remained significantly associated with cognitive functioning after adjustment for gender, age, education, NYHA functional class, arterial hypertension, smoking, medication use (nitrates and beta-blockers), LVEF, BMI, and HADS-D score.
Results
Socio-demographic and clinical characteristics as well as HADS-D and cognitive functioning scores of 278 patients are all listed in Table 1 . Descriptive statistics are presented as number of cases, percentage, and means with standard deviations (SD) for qualitative and quantitative variables, respectively. The distributions for the NT-proBNP and hsCRP values were asymmetric and are presented as median and 25 and 75 percentiles.
The study sample consisted of 206 (74%) male patients and 72 (26%) female patients (mean age 58; SD = 9). Most patients (n = 167, 60%) had MI, and 111 (40%) patients had unstable angina pectoris. The majority of patients (n = 199, 72%) were characterized as NYHA functional class II, followed by NYHA functional class III (n = 45, 16%) and NYHA functional class I (n = 34, 12%). Two-hundred and forty-five (88%) patients were being treated with beta-blockers, while 94 (34%) were taking nitrates. Table 2 shows the associations of fT3, TT3, (ln)NT-proBNP, and (ln)hsCRP with cognitive function measures in unadjusted and adjusted models. In unadjusted models, almost all independent variables including fT3, TT3, (ln)NT-proBNP, and (ln)hsCRP were associated with cognitive function: both lower fT3 and TT3 levels were associated with worse performance on the MMSE (β = .167, p = .005; β = .177, p = .003), worse DSST raw score (β = .204, p = .001; β = .171, p = .005), longer DSST completion time (β = −.209, p < .001; β = −.165, p = .006), and an inferior score on the TMTA (β = −.239, p < .001; β = −.190, p = .002). A lower fT3 level was also associated with fewer DSST pairs recalled correctly (β = .181, p = .002). In univariate models, higher (ln)NT-proBNP and (ln)hsCRP levels were associated, respectively, with inferior DSST raw scores (β = −.163, p = .007; β = .163, p = .007) and longer time needed to complete the DSST (β = .193, p = .001; β = .165, p = .006). Higher (ln)NT-proBNP levels were associated with inferior performance on the TMTA (β = .202, p = .001). FT3, TT3, (ln)NT-proBNP, and (ln)hsCRP concentrations were not associated with DST in univariate analyses; therefore, DST results were not considered for further multivariate regression models.
After adjustment for age, gender, education, NYHA functional class, LVEF, arterial hypertension, smoking, obesity, medication use, and HADS-D score, lower fT3 concentration remained significantly associated with longer DSST completion time Notes: NYHA = New York Heart Association; CAD = coronary artery disease; DST = Digit Span Test; DSST = Digit Symbol Substitution Test; MI = myocardial infarction; BMI = body mass index; LVEF = left ventricular ejection fraction; MMSE = Mini-Mental State Examination; HADS-D = Hospital Anxiety and Depression Scale-depression subscale; NT-proBNP = N-terminal pro-B-type natriuretic peptide; hsCRP = high-sensitivity C-reactive protein; fT3 = free triiodothyronine; TT3 = total triiodothyronine.
(β = −.175, p < .03) and with longer time to complete TMTA (β = −.173, p < .04). Greater concentration of (ln)NT-proBNP was negatively associated with the TMTA completion time (β = −.142, p < .03). TT3 and (ln)hsCRP concentrations were not associated with cognitive functioning in multivariate regression analyses.
Discussion
Our findings demonstrate that in CAD patients after ACS, fT3, and NT-proBNP concentrations are associated with cognitive functions, adjusting for socio-demographic characteristics, clinical risk factors, and depressive symptom severity. Specifically, lower fT3 concentrations were independently associated with worse performance on cognitive tests that require longer time for completion while greater NT-proBNP concentration was associated with decreased perceptual speed. However, hsCRP was not associated with cognitive functions in adjusted models.
The aforementioned results show the importance of fT3 on cognitive function in CAD patients during rehabilitation. Our study echoes results by Bojar and colleague (2014) , demonstrating that lower fT3 concentration is linked to slower perceptual speed among stable CAD patients after ACS. Thus, evaluation for thyroid axis functioning should be considered in CAD patients with cognitive impairment, and patients with clinical thyroid axis dysfunction should be appropriately managed.
Studies show that lower fT3, and higher NT-proBNP, hsCRP levels are associated with worse patient-oriented and clinical outcomes for CAD patients (Brozaitiene, Mickuviene, Podlipskyte, Burkauskas, & Bunevicius, 2016; Koenig, 2013) . It would be important to examine whether cognitive decline is a mediator, moderator, or independent factor in the association between negative patient-oriented, clinical outcomes, and thyroid hormones, NT-proBNP, hsCRP levels. In addition, it remains unclear if treatment of subclinical thyroid disorders can improve prognosis and cognitive functioning of CAD patients.
We found that greater NT-proBNP concentration was associated with worse perceptual speed independently from sociodemographic characteristics, clinical risk factors, and depressive symptoms. Similarly, in the Leiden 85-plus study of 560 elderly participants, van Vliet and colleague (2014) found that high NT-proBNP levels (552.9-28 362.7 pg/ml) were associated with lower MMSE scores after 5 years. The inverse association of NT-proBNP concentrations and cognitive functioning was subsequently confirmed in the study by Mirza and colleague (2016) , who showed that higher levels of NT-proBNP contributed to the increase risk of dementia and cognitive decline at 10-year follow-ups in the general population (mean age of 69 years). We did not find an association between NT-proBNP concentration and MMSE score. These discrepancies can be explained by the fact that our study sample included younger subjects (mean age: 58) with low to medium range of NTproBNP levels (range from 112.0 to 652.4 pg/ml). It is possible that NT-proBNP levels do not affect global cognitive functioning until very old age, but they may contribute to slower perceptual speed even at a younger age, as was found in our study. Biological mechanisms underlying the association of NT-proBNP with cognitive functioning as a function of age require further investigation, as such knowledge could indicate whether NT-proBNP could serve as a potential biomarker for future cognitive decline.
We did not find an association of hsCRP concentration with cognitive functioning domains in adjusted regression analyses. A study by Bunevicius and colleague (2015) in 78 acute stroke patients within 48 hr of symptom onset found that greater hsCRP serum concentration on admission was associated with worse cognitive outcomes at discharge independent of patients' age, gender, clinical stroke severity, and presence of congestive heart failure, suggesting that greater immune system activation in the acute stroke setting could contributed to worse cognitive sequelae. Lack of association between hsCRP and cognitive functioning in the present study can be explained by the fact that the immune system may be less activated in ACS relative to stroke. Also, our patients were at stable disease phase when immune system response might have declined in comparison to immune system response during ACS. Indeed, it has been shown that pro-inflammatory cytokine concentrations decline with recovery from illness (Nian, Lee, Khaper, & Liu, 2004) .
The strengths of our study include well-validated tests for measuring cognitive functions as well as a moderate sample size that allowed us to adjust our results for variables that could contribute to impaired cognition, such as clinical risk factors and depression. The large number of biomarkers collected is another strength of the present study.
A cross-sectional design is a major limitation of our study, which prevented us from evaluating a causal relationship of fT3, NT-proBNP concentrations with cognitive functions. Inclusion of patients undergoing cardiac rehabilitation limits generalizability of our findings to acute CAD patients. Also, our results should not be generalized to CAD patients of >80 years old, patients with previous cerebrovascular accidents, and patients with severe somatic disorders as these were the study exclusion criteria. Understanding of other neurocognitive effects of fT3, NT-proBNP should be elucidated in future studies employing other focused and specific cognitive functioning assessment probes because such knowledge could facilitate identification of novel therapeutic strategies.
Conclusions
During rehabilitation of stable CAD patients after ACS, lower fT3 concentrations are associated with worse perceptual speed and inferior efficacy of completing cognitive tasks. Moreover, NT-proBNP is negatively associated with perceptual speed, independently of clinical risk factors and depressive symptoms. Our findings further exemplify the importance of thyroid hormones and NT-proBNP on cognitive functioning during the rehabilitation period of patients after ACS. The alterations in cognitive functioning during this period may be subtle, requiring further studies to analyze the potential longitudinal effect of these changes.
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